Identification and characterization of Sofosbuvir‐resistant mutations of hepatitis C virus genotype 3a replicon
Journal of Medical Virology · 2023
DOI: 10.1002/jmv.29290 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Jackline Wangu Ngari und 5 weiteren Autor:innen. Beteiligte Einrichtung: CAS Key Laboratory of Molecular Virology and Immunology, Unit of Viral Hepatitis, Shanghai Institute of Immunity and Infection, Chinese Academy of Sc…. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Hepatitis C. Die Arbeit nennt 15 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai International Science and Technology Cooperation Program, Shanghai Municipal Science and Technology Major Project.
Abstract (Originalsprache)
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease worldwide. Among its 8 genotypes (GT), GT3 has a relatively lower sustained virological response to highly effective direct‐acting antiviral agents (DAA). Sofosbuvir (SOF), an anti‐NS5B polymerase inhibitor, is a core component of many anti‐HCV DAA cocktail regimens, and its resistant mutations are rare in clinics because these mutations usually severely impair the NS5B polymerase activity, including a mutation S282T in NS5B, the most frequently reported SOF‐resistant mutation. In this study, we selected SOF‐resistant variants of a previously developed GT3 subgenomic replicon (PR87A7). Two mutations were identified in the viral genome of SOF‐resistant PR87A7 variants, Q606R in nontargeted NS3 and S282T in targeted N5SB. We demonstrated that Q606R could rescue the replication defect of S282T in PR87A7, and the resulting double mutant confers the SOF resistance. Finally, we showed that NS3‐606R could not compensate for the replication defect of S282T in other GTs. In conclusion, we identified a novel GT3‐specific combination of two mutations that confers SOF resistance. Our result calls for attention to potential mutations that may arise in nontargeted viral proteins during the SOF‐based DAA treatment of chronic HCV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CAS Key Laboratory of Molecular Virology and Immunology, Unit of Viral Hepatitis, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Shanghai, China.
- Savaid Medical School, University of Chinese Academy of Sciences, Beijing, China.
- School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
ORCID-Profile: Jin Zhong
Förderung
- National Natural Science Foundation of China
- Shanghai International Science and Technology Cooperation Program
- Shanghai Municipal Science and Technology Major Project
- Program of Shanghai Academic/Technology Research Leader
Zitieren
APA
Ngari, J. W., Leumi, S., Han, L., Liu, C., Tong, Y., & Zhong, J. (2023). Identification and characterization of Sofosbuvir‐resistant mutations of hepatitis C virus genotype 3a replicon. Journal of Medical Virology. https://doi.org/10.1002/jmv.29290
Vancouver
Ngari JW, Leumi S, Han L, Liu C, Tong Y, Zhong J. Identification and characterization of Sofosbuvir‐resistant mutations of hepatitis C virus genotype 3a replicon. Journal of Medical Virology. 2023. doi:10.1002/jmv.29290
BibTeX
@article{Ngari2023,
author = {Ngari, Jackline Wangu and Leumi, Steve and Han, Lin and Liu, Chaolun and Tong, Yimin and Zhong, Jin},
title = {Identification and characterization of Sofosbuvir‐resistant mutations of hepatitis C virus genotype 3a replicon},
journal = {Journal of Medical Virology},
year = {2023},
doi = {10.1002/jmv.29290}
}
EUVIMED